Press coverage about Kindred Biosciences (NASDAQ:KIN) has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.4815192208233 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of KIN traded up $0.10 during mid-day trading on Thursday, hitting $8.45. The company’s stock had a trading volume of 84,278 shares, compared to its average volume of 80,754. The stock has a market capitalization of $231.15, a P/E ratio of -6.87 and a beta of 0.08. Kindred Biosciences has a 1-year low of $6.50 and a 1-year high of $9.80.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). sell-side analysts expect that Kindred Biosciences will post -1.5 EPS for the current fiscal year.
In other Kindred Biosciences news, Director Raymond Townsend sold 2,670 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $9.45, for a total transaction of $25,231.50. Following the completion of the transaction, the director now owns 25,057 shares of the company’s stock, valued at $236,788.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Richard Chin sold 20,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $8.39, for a total value of $167,800.00. Following the transaction, the insider now directly owns 2,266,071 shares of the company’s stock, valued at approximately $19,012,335.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,761 shares of company stock valued at $193,891. 19.10% of the stock is currently owned by insiders.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.